PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26345150-19 2015 In the aspirin-treated group compared to the control group, the NE had a protective effect on the stomach and caused less injury than aspirin, indicated by significant decreases in TNFalpha, iNOS, prostaglandin E2, and malondialdehyde levels, and also significant increases in glutathione, glutathione reductase, glutathione peroxidase, catalase, and superoxide dismutase. Aspirin 7-14 nitric oxide synthase 2 Rattus norvegicus 191-195 32295429-11 2020 Aspirin enhanced the immunoexpression of inducible nitric oxide synthetase (iNOS) and increased the level of nitrite/nitrate in gastric tissue. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 41-74 32295429-11 2020 Aspirin enhanced the immunoexpression of inducible nitric oxide synthetase (iNOS) and increased the level of nitrite/nitrate in gastric tissue. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 76-80 31781346-11 2019 Histological analysis showed that aspirin treatment prevented the loss of COL2 and decreased MMP-3 and MMP-13, inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), IL-1beta, and TNF-alpha expression in the IVD tissues. Aspirin 34-41 nitric oxide synthase 2 Rattus norvegicus 111-132 27825819-15 2016 ASA caused hemorrhagic gastric mucosal damage and significantly decreased GBF, H2S production, CO content, mRNA or protein expression for CSE, 3-MST, HO-2 and increased mRNA and/or protein expression for CBS, HO-1, Nrf-2, HIF-1alpha, iNOS, IL-1beta, COX-2 in gastric mucosa and COHb concentration in blood. Aspirin 0-3 nitric oxide synthase 2 Rattus norvegicus 234-238 26345150-0 2015 The effect of aspirin nanoemulsion on TNFalpha and iNOS in gastric tissue in comparison with conventional aspirin. Aspirin 14-21 nitric oxide synthase 2 Rattus norvegicus 51-55 31781346-11 2019 Histological analysis showed that aspirin treatment prevented the loss of COL2 and decreased MMP-3 and MMP-13, inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), IL-1beta, and TNF-alpha expression in the IVD tissues. Aspirin 34-41 nitric oxide synthase 2 Rattus norvegicus 134-138 20233223-2 2010 Here, we have assessed the role played by NO, formed by inducible NOS (iNOS), in the inflammation induced by aspirin in the gut, by modulating HIF-1 activity. Aspirin 109-116 nitric oxide synthase 2 Rattus norvegicus 56-69 20233223-2 2010 Here, we have assessed the role played by NO, formed by inducible NOS (iNOS), in the inflammation induced by aspirin in the gut, by modulating HIF-1 activity. Aspirin 109-116 nitric oxide synthase 2 Rattus norvegicus 71-75 26379739-6 2015 Treatment of aspirin alone significantly reduced the expressions of HO-1 (P < 0.001), iNOS (P < 0.001), and Bax (P < 0.01) in ischemic regions. Aspirin 13-20 nitric oxide synthase 2 Rattus norvegicus 89-93 19730809-0 2009 Aspirin attenuates insulin resistance in muscle of diet-induced obese rats by inhibiting inducible nitric oxide synthase production and S-nitrosylation of IRbeta/IRS-1 and Akt. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 89-120 20079805-11 2010 The activity of the inducible isoform (iNOS) was inhibited by the three types of treatment (-31.8% for ASA, -29.1% for VOO and -56.0% for ASA plus VOO). Aspirin 103-106 nitric oxide synthase 2 Rattus norvegicus 39-43 20079805-11 2010 The activity of the inducible isoform (iNOS) was inhibited by the three types of treatment (-31.8% for ASA, -29.1% for VOO and -56.0% for ASA plus VOO). Aspirin 138-141 nitric oxide synthase 2 Rattus norvegicus 39-43 20233223-3 2010 EXPERIMENTAL APPROACH: The role of iNOS-derived NO on leucocyte-endothelial interactions induced by aspirin was evaluated by intravital microscopy in mesenteric venules of rats pretreated with selective iNOS inhibitors, 1400W or l-N6-(1-iminoethyl)-lysine. Aspirin 100-107 nitric oxide synthase 2 Rattus norvegicus 35-39 20233223-8 2010 iNOS expression and iNOS-derived NO synthesis were observed in leucocytes of the mesentery of aspirin-treated rats. Aspirin 94-101 nitric oxide synthase 2 Rattus norvegicus 0-4 20233223-8 2010 iNOS expression and iNOS-derived NO synthesis were observed in leucocytes of the mesentery of aspirin-treated rats. Aspirin 94-101 nitric oxide synthase 2 Rattus norvegicus 20-24 20233223-9 2010 Blockade of iNOS activity in aspirin-treated rats: (i) did not modify leucocyte infiltration at 6 h, but reduced the number of polymorphonuclear leucocyte and increased that of macrophages at 24 h; (ii) increased HIF-1alpha immunostaining in macrophages of the mesentery; and (iii) prevented the decrease in CD36 immunostaining induced by aspirin in these cells. Aspirin 29-36 nitric oxide synthase 2 Rattus norvegicus 12-16 20233223-9 2010 Blockade of iNOS activity in aspirin-treated rats: (i) did not modify leucocyte infiltration at 6 h, but reduced the number of polymorphonuclear leucocyte and increased that of macrophages at 24 h; (ii) increased HIF-1alpha immunostaining in macrophages of the mesentery; and (iii) prevented the decrease in CD36 immunostaining induced by aspirin in these cells. Aspirin 339-346 nitric oxide synthase 2 Rattus norvegicus 12-16 19730809-2 2009 In this study, we investigated the effects of aspirin treatment on inducible nitric oxide synthase (iNOS)-mediated insulin resistance and on S-nitrosylation of insulin receptor (IR)-beta, IRS-1 and protein kinase B (Akt) in the muscle of diet-induced obese rats and also in iNos (also known as Nos2)-/- mice on high fat diet. Aspirin 46-53 nitric oxide synthase 2 Rattus norvegicus 67-98 19730809-2 2009 In this study, we investigated the effects of aspirin treatment on inducible nitric oxide synthase (iNOS)-mediated insulin resistance and on S-nitrosylation of insulin receptor (IR)-beta, IRS-1 and protein kinase B (Akt) in the muscle of diet-induced obese rats and also in iNos (also known as Nos2)-/- mice on high fat diet. Aspirin 46-53 nitric oxide synthase 2 Rattus norvegicus 100-104 19730809-7 2009 Conversely, while aspirin reversed the increased phosphorylation of IkappaB kinase beta and c-Jun amino-terminal kinase, as well as IRS-1 serine phosphorylation in diet-induced obese rats and iNos -/- mice on high-fat diet, these alterations were not associated with the improvement of insulin action induced by this drug. Aspirin 18-25 nitric oxide synthase 2 Rattus norvegicus 192-196 19730809-8 2009 CONCLUSIONS/INTERPRETATION: Our data demonstrate that aspirin treatment not only reduces iNOS protein levels, but also S-nitrosylation of IRbeta, IRS-1 and Akt. Aspirin 54-61 nitric oxide synthase 2 Rattus norvegicus 89-93 16310244-7 2006 The data also showed that NF-kappaB activation and its associated gene expressions, such as COX-2, iNOS, VCAM-1 and ICAM-1, were all suppressed by the low dose aspirin supplementation through the inhibition of phosphorylation and degradation of IkappaBalpha via the NIK/IKK pathway. Aspirin 160-167 nitric oxide synthase 2 Rattus norvegicus 99-103 16545519-10 2006 Nitric oxide production after 180 min reoxygenation was significantly reduced in aspirin (36.4%), alpha-tocopherol (22.7%) and aspirin-alpha-tocopherol (77.8%) treated rats with respect to diabetic non-treated animals; this was related mainly with a reduction in iNOS activity. Aspirin 81-88 nitric oxide synthase 2 Rattus norvegicus 263-267 16545519-10 2006 Nitric oxide production after 180 min reoxygenation was significantly reduced in aspirin (36.4%), alpha-tocopherol (22.7%) and aspirin-alpha-tocopherol (77.8%) treated rats with respect to diabetic non-treated animals; this was related mainly with a reduction in iNOS activity. Aspirin 127-134 nitric oxide synthase 2 Rattus norvegicus 263-267 17526656-9 2007 In addition, NO-aspirin downregulated inducible NO synthase (iNOS; 0.37-fold, P < 0.01) and cyclooxygenase-2 (COX-2; 0.61-fold, P < 0.05) gene expression compared with the vehicle group after 48 h of reperfusion. Aspirin 16-23 nitric oxide synthase 2 Rattus norvegicus 38-59 17526656-9 2007 In addition, NO-aspirin downregulated inducible NO synthase (iNOS; 0.37-fold, P < 0.01) and cyclooxygenase-2 (COX-2; 0.61-fold, P < 0.05) gene expression compared with the vehicle group after 48 h of reperfusion. Aspirin 16-23 nitric oxide synthase 2 Rattus norvegicus 61-65 16797507-3 2006 A significant increase in vascular permeability, NOS-2 activity, TNF-alpha, IL-1beta levels and oxidative damage were noted in aspirin administered rats. Aspirin 127-134 nitric oxide synthase 2 Rattus norvegicus 49-54 15882795-3 2005 Using Western Blotting, we verified that aspirin enhanced LPS-induced iNOS expression and the presence of 15-deoxy-Delta(12,14)-prostaglandin (15d-PGJ2) suppressed this aspirin effect. Aspirin 41-48 nitric oxide synthase 2 Rattus norvegicus 70-74 16094491-3 2005 Three parts were performed in the present experiment: (1) To determine the effects of pretreatment with aspirin against heatstroke;(2) To prove the effects of specifically reducing inducible nitric oxide synthase (iNOS) against rat heatstroke by iNOS selective prohibitor aminoguanidine (AG);(3) To determine the effects of aspirin against heatstroke and fatigue. Aspirin 104-111 nitric oxide synthase 2 Rattus norvegicus 181-212 16094491-3 2005 Three parts were performed in the present experiment: (1) To determine the effects of pretreatment with aspirin against heatstroke;(2) To prove the effects of specifically reducing inducible nitric oxide synthase (iNOS) against rat heatstroke by iNOS selective prohibitor aminoguanidine (AG);(3) To determine the effects of aspirin against heatstroke and fatigue. Aspirin 324-331 nitric oxide synthase 2 Rattus norvegicus 181-212 16094491-3 2005 Three parts were performed in the present experiment: (1) To determine the effects of pretreatment with aspirin against heatstroke;(2) To prove the effects of specifically reducing inducible nitric oxide synthase (iNOS) against rat heatstroke by iNOS selective prohibitor aminoguanidine (AG);(3) To determine the effects of aspirin against heatstroke and fatigue. Aspirin 324-331 nitric oxide synthase 2 Rattus norvegicus 214-218 16094491-15 2005 In conclusion, IL-1betamay contribute to heatstroke through inducing iNOS, which attenuates the tone of peripheral blood vessel, and pretreatment with aspirin can provide preventive effects against heatstroke and reinforce the heat and fatigue endurance, which may be associated with inhibition of systemic IL-1betalevels and local iNOS levels. Aspirin 151-158 nitric oxide synthase 2 Rattus norvegicus 332-336 15882795-2 2005 The aim of this study was to evaluate the effect of high-level aspirin on iNOS expression in cultured rat glial cells treated with lipopolysaccharide (LPS) as pathological stimulator. Aspirin 63-70 nitric oxide synthase 2 Rattus norvegicus 74-78 15882795-5 2005 These results suggest that aspirin interferes with the cross-talk of prostaglandins and NO, blocking the endogenous negative control exerted by COX products on iNOS expression. Aspirin 27-34 nitric oxide synthase 2 Rattus norvegicus 160-164 15882795-6 2005 On the other side, aspirin seems to act directly on iNOS reducing its activity, even if it does not completely block NO release by LPS-stimulated glial cells. Aspirin 19-26 nitric oxide synthase 2 Rattus norvegicus 52-56 14705149-4 2004 In brain tissue subjected to hypoxia, ASA reduced oxidative stress and iNOS activity (all increased by hypoxia), but only when used at higher concentrations. Aspirin 38-41 nitric oxide synthase 2 Rattus norvegicus 71-75 15157801-10 2004 Inducible NO synthase activity was reduced by 25%, 27% and 30% with triflusal, and 0%, 25% and 24% with ASA. Aspirin 104-107 nitric oxide synthase 2 Rattus norvegicus 0-21 10818069-4 2000 Increased nitrite production by aspirin-like drugs was accompanied by increased iNOS mRNA and protein accumulation in VSMCs. Aspirin 32-39 nitric oxide synthase 2 Rattus norvegicus 80-84 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 141-172 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 174-178 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 9-29 nitric oxide synthase 2 Rattus norvegicus 141-172 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 9-29 nitric oxide synthase 2 Rattus norvegicus 174-178 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 31-34 nitric oxide synthase 2 Rattus norvegicus 141-172 12124433-1 2002 Aspirin [acetylsalicylic acid (ASA)] is an anti-inflammatory drug that protects against cellular injury by inhibiting cyclooxygenases (COX), inducible nitric oxide synthase (iNOS) and p44/42 mitogen-activated protein kinase (p44/42 MAPK), or by preventing translocation of nuclear factor kappaB (NF-kappaB). Aspirin 31-34 nitric oxide synthase 2 Rattus norvegicus 174-178 11287034-0 2001 Aspirin dose dependently inhibits the interleukin-1 beta-stimulated increase in inducible nitric oxide synthase, nitric oxide, and prostaglandin E(2) production in rat ovarian dispersates cultured in vitro. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 80-111 11287034-1 2001 OBJECTIVE: Determine if aspirin inhibits the IL-1 beta-stimulated expression of inducible nitric oxide synthase (iNOS), nitric oxide (NO), and prostaglandin E(2) (PGE(2)) in rat ovarian dispersates cultured in vitro. Aspirin 24-31 nitric oxide synthase 2 Rattus norvegicus 80-111 11287034-1 2001 OBJECTIVE: Determine if aspirin inhibits the IL-1 beta-stimulated expression of inducible nitric oxide synthase (iNOS), nitric oxide (NO), and prostaglandin E(2) (PGE(2)) in rat ovarian dispersates cultured in vitro. Aspirin 24-31 nitric oxide synthase 2 Rattus norvegicus 113-117 11287034-12 2001 Coadministration of IL-1 beta and aspirin (10 mM) attenuates IL-1 beta-stimulated iNOS expression after culture for 24 and 48 hours. Aspirin 34-41 nitric oxide synthase 2 Rattus norvegicus 82-86 11287034-13 2001 CONCLUSION(S): Aspirin significantly inhibits the IL-1 beta-stimulated expression of iNOS, NO, and PGE(2) in ovarian dispersates cultured in vitro. Aspirin 15-22 nitric oxide synthase 2 Rattus norvegicus 85-89 10818069-8 2000 Our study demonstrates that aspirin and the aspirin-like drugs, sodium salicylate and indomethacin, increase NO synthesis in IL-1beta-stimulated VSMCs by upregulation of iNOS transcription via a 12-LO pathway. Aspirin 28-35 nitric oxide synthase 2 Rattus norvegicus 170-174 10818069-8 2000 Our study demonstrates that aspirin and the aspirin-like drugs, sodium salicylate and indomethacin, increase NO synthesis in IL-1beta-stimulated VSMCs by upregulation of iNOS transcription via a 12-LO pathway. Aspirin 44-51 nitric oxide synthase 2 Rattus norvegicus 170-174 10203355-14 1999 It can be concluded that (1) iNOS can be induced without active NF-kappaB; (2) Dex, acetylsalicylic acid, and PDTC inhibit only p65; and (3) JAK2 is involved in iNOS induction, and the contribution of JAK2 to nitrite production is greater than that of NF-kappaB. Aspirin 84-104 nitric oxide synthase 2 Rattus norvegicus 161-165 10218970-6 1999 Dexamethasone, salicylate and aspirin, but not indomethacin, dose dependently inhibited cytokine-stimulated NOx production and iNOS protein expression. Aspirin 30-37 nitric oxide synthase 2 Rattus norvegicus 127-131 10218970-10 1999 Aspirin dose dependently inhibited iNOS enzymatic activity, whereas salicylate and dexamethasone had limited effect. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 35-39 9718067-5 1998 Aspirin and sodium salicylate enhance the induction of iNOS expression by IL-1beta. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 55-59 9718067-8 1998 Aspirin and sodium salicylate ameliorate the down-regulation of iNOS expression and the decrease of NO production caused by pretreatment with high glucose (25 mM). Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 64-68 9718067-0 1998 Aspirin and salicylate enhances the induction of inducible nitric oxide synthase in cultured rat smooth muscle cells. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 49-80 9718067-9 1998 These results suggest a possible therapeutic role in atherosclerotic disease and diabetes mellitus for aspirin and sodium salicylate by enhancing the level of iNOS expression and NO production. Aspirin 103-110 nitric oxide synthase 2 Rattus norvegicus 159-163 8620595-10 1996 These studies implicate cardiac fibroblasts as a source of NO in inflammatory cardiac diseases and suggest a possible therapeutic role for salicylate and aspirin in diminishing the steady state levels of iNOS mRNA. Aspirin 154-161 nitric oxide synthase 2 Rattus norvegicus 204-208 9281601-7 1997 Aspirin at high concentrations of 10 and 20 mM inhibited de novo protein synthesis as demonstrated by inhibition of [35S]methionine incorporation into total islet protein and by inhibition of rabbit reticulocyte expression by Brome mosaic virus mRNA, suggesting that inhibition of iNOS expression at these high concentrations of aspirin may be due to the impairment of the translational machinery. Aspirin 0-7 nitric oxide synthase 2 Rattus norvegicus 281-285 9281601-8 1997 These findings indicate that inhibition of iNOS expression and NO production may explain, in part, the beneficial effects of aspirin as an anti-inflammatory agent at therapeutic concentrations, whereas inhibition of de novo protein synthesis may possibly explain clinical and side effects of aspirin in the inflamed tissues and organs such as stomach and kidney that may accumulate high concentrations of aspirin. Aspirin 125-132 nitric oxide synthase 2 Rattus norvegicus 43-47 33222458-11 2021 Moreover, XST+ASA+CLP group also had lower levels of NOX2, inducible nitric oxide synthase (iNOS), interleukin (IL)-6, and p-STAT3/STAT3. Aspirin 14-17 nitric oxide synthase 2 Rattus norvegicus 59-90 33222458-11 2021 Moreover, XST+ASA+CLP group also had lower levels of NOX2, inducible nitric oxide synthase (iNOS), interleukin (IL)-6, and p-STAT3/STAT3. Aspirin 14-17 nitric oxide synthase 2 Rattus norvegicus 92-96